Eli Lilly and Co banner

Eli Lilly and Co
XBER:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
XBER:LLY
Watchlist
Price: 913.5 EUR
Market Cap: €868.2B

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is hidden EUR. Compared to the current market price of 913.5 EUR, Eli Lilly and Co is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
XBER:LLY
860.3B EUR 13.2 41.7 28.1 30
US
Johnson & Johnson
NYSE:JNJ
566.9B USD 6 21.1 14.7 18.1
CH
Roche Holding AG
SIX:ROG
243.3B CHF 3.9 18.8 11.2 12.6
UK
AstraZeneca PLC
LSE:AZN
213.1B GBP 4.9 28 15.6 21.9
US
Merck & Co Inc
NYSE:MRK
286.3B USD 4.4 15.7 9.7 11.9
CH
Novartis AG
SIX:NOVN
222.8B CHF 5.1 20.6 12.8 16.4
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.3 7.7 9
US
Pfizer Inc
NYSE:PFE
152.2B USD 2.4 19.6 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
114.7B USD 2.4 16.3 6.9 8.5
FR
Sanofi SA
PAR:SAN
92.9B EUR 2 12 10.1 10.1
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
XBER:LLY
Average P/E: 20.4
41.7
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.1
7%
3
CH
Roche Holding AG
SIX:ROG
18.8
14%
1.3
UK
AstraZeneca PLC
LSE:AZN
28
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.7
14%
1.1
CH
Novartis AG
SIX:NOVN
20.6
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.3
16%
1
FR
Sanofi SA
PAR:SAN
12
16%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
XBER:LLY
Average EV/EBITDA: 45.4
28.1
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.4
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
15.6
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.7
3%
3.2
CH
Novartis AG
SIX:NOVN
12.8
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
1%
7.7
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.9
-10%
N/A
FR
Sanofi SA
PAR:SAN
10.1
19%
0.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
XBER:LLY
Average EV/EBIT: 99.1
30
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.1
6%
3
CH
Roche Holding AG
SIX:ROG
12.6
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
21.9
21%
1
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
CH
Novartis AG
SIX:NOVN
16.4
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.5
-7%
N/A
FR
Sanofi SA
PAR:SAN
10.1
12%
0.8
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett